Contralateral R1 in Amyotrophic Lateral Sclerosis

NCT ID: NCT06206629

Last Updated: 2024-10-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-15

Study Completion Date

2024-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting both upper and lower motor neurons. Electroneuromyography is an important tool for the diagnosis. Previous studies have shown that different components of the blink reflex, such as the latencies of homo- and contralateral R2 responses can be affected. Studies have found that a contralateral R1 component can appear in neurological diseases with affection of the central nervous system especially upper motor neuron, such as HTLV1 infection. Thus, you aim to determine if a contralateral R1 component could be present in ALS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALS patients

Patients with ALS (Awaji criteria)

blink reflex evaluation

Intervention Type DIAGNOSTIC_TEST

A blink reflex evaluation will be performed in all subjects

Non-ALS patients

Patients referred to the neurophysiology unit for a suspicion of ALS du to motor weakness, but in whom the diagnosis is ruled out.

blink reflex evaluation

Intervention Type DIAGNOSTIC_TEST

A blink reflex evaluation will be performed in all subjects

Healthy volunteers

Healthy volunteers who will undergo a blink reflex evaluation on ENMG.

blink reflex evaluation

Intervention Type DIAGNOSTIC_TEST

A blink reflex evaluation will be performed in all subjects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blink reflex evaluation

A blink reflex evaluation will be performed in all subjects

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For patients

* Aged 18 to 99 years old
* Referred for suspected motor neuromuscular disease
* Collection of non-opposition

For healthy subjects:

* Aged 18 to 99 years old
* Absence of any neurological pathology
* Collection of non-opposition

Exclusion Criteria

* Previous damage linked to another cause of the cranial nerves
* Prior brainstem lesions
* Persons deprived of liberty by a judicial or administrative decision
* Patient under judicial protection, unable to express consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital neurologique Pierre Wertheimer

Bron, Rhone, France

Site Status

CHU de Nantes

Nantes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL23_1291

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.